The biocompatibility of surface-modified biphasic calcium phosphate （mBCP）/poly-L-Lactide （PLLA） biocomposite was investigated through a series of experiments in vitro and in vivo. Acute toxicity and short term sy...The biocompatibility of surface-modified biphasic calcium phosphate （mBCP）/poly-L-Lactide （PLLA） biocomposite was investigated through a series of experiments in vitro and in vivo. Acute toxicity and short term systemic toxicity experiments revealed no toxicity of the materials. Hemolysis assay indicated the good blood compatibility of the composite. In cytotoxicity assay, L929 mouse fibroblasts could well differentiate and proliferate. Animal experiments in vivo were.performed by implanting the materials into rabbits muscle for 8 weeks. The decreasing of inflammatory cells, the building of fibrous tissue layer as well as the growing of blood cells into materials indicated the nontoxicity of the composite. Based on the experiment results, surfacemodified BCP/PLLA biocomposite is proven to have superior biocompatibility, which would be a promising bone repairing material.展开更多
Biphasic calcium phosphate （BCP） powders were prepared by hydrolyzation proc-ess and surface-modified by directly grafted L-lactide （LLA） onto the surface of BCP through a chemical linkage. The grafting ratio of o...Biphasic calcium phosphate （BCP） powders were prepared by hydrolyzation proc-ess and surface-modified by directly grafted L-lactide （LLA） onto the surface of BCP through a chemical linkage. The grafting ratio of organic groups was 9 wt%. After surface modification, the surface of BCP powders was covered by the lamella-shaped crystal. Poly （L-lactide） was mixed with BCP to form the BCP/PLLA biocomposite. Modified BCP （mBCP） particles could be uniformly dis-persed in PLLA matrix. The compressive strength of the mBCP/PLLA composite is 115 MPa, 28% higher than that of unmodified-BCP/PLLA composite. The improved mechanical strength is attributed to the enhanced adhesion between the inorganic BCP filler and the organic PLLA matrix.展开更多
基金supported by Doctoral Fund of Ministry of Education of China under grant No.20060610024
文摘The biocompatibility of surface-modified biphasic calcium phosphate （mBCP）/poly-L-Lactide （PLLA） biocomposite was investigated through a series of experiments in vitro and in vivo. Acute toxicity and short term systemic toxicity experiments revealed no toxicity of the materials. Hemolysis assay indicated the good blood compatibility of the composite. In cytotoxicity assay, L929 mouse fibroblasts could well differentiate and proliferate. Animal experiments in vivo were.performed by implanting the materials into rabbits muscle for 8 weeks. The decreasing of inflammatory cells, the building of fibrous tissue layer as well as the growing of blood cells into materials indicated the nontoxicity of the composite. Based on the experiment results, surfacemodified BCP/PLLA biocomposite is proven to have superior biocompatibility, which would be a promising bone repairing material.
基金Funded by the Research Fund for the Doctoral Program of Higher Education of China (No. 20060610024)
文摘Biphasic calcium phosphate （BCP） powders were prepared by hydrolyzation proc-ess and surface-modified by directly grafted L-lactide （LLA） onto the surface of BCP through a chemical linkage. The grafting ratio of organic groups was 9 wt%. After surface modification, the surface of BCP powders was covered by the lamella-shaped crystal. Poly （L-lactide） was mixed with BCP to form the BCP/PLLA biocomposite. Modified BCP （mBCP） particles could be uniformly dis-persed in PLLA matrix. The compressive strength of the mBCP/PLLA composite is 115 MPa, 28% higher than that of unmodified-BCP/PLLA composite. The improved mechanical strength is attributed to the enhanced adhesion between the inorganic BCP filler and the organic PLLA matrix.
